

# Natasha Woodward

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7633485/publications.pdf>

Version: 2024-02-01

30  
papers

1,008  
citations

933447

10  
h-index

677142

22  
g-index

30  
all docs

30  
docs citations

30  
times ranked

1834  
citing authors

#	ARTICLE	IF	CITATIONS
1	Incorporation of eribulin in the systemic treatment of metastatic breast cancer patients in Australia. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2022, 18, 201-208.	1.1	2
2	Letter to the editor: re Lu et al.. <i>Supportive Care in Cancer</i> , 2021, 29, 1-2.	2.2	0
3	Predicting endocrine sensitivity in breast cancer. <i>Pathology</i> , 2021, 53, S2.	0.6	0
4	Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial. <i>Annals of Oncology</i> , 2020, 31, 1526-1535.	1.2	214
5	A first-in-human, phase 1, dose-escalation study of ABBV-176, an antibody-drug conjugate targeting the prolactin receptor, in patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2020, 38, 1815-1825.	2.6	12
6	Development of novel biomarkers predictive of endocrine sensitivity in breast cancer. <i>Pathology</i> , 2020, 52, S8.	0.6	0
7	Outcomes in Clinically Relevant Patient Subgroups From the EMBRACA Study: Talazoparib vs Physician's Choice Standard-of-Care Chemotherapy. <i>JNCI Cancer Spectrum</i> , 2020, 4, pkz085.	2.9	24
8	Results From the First Multicenter, Open-label, Phase IIIb Study Investigating the Combination of Pertuzumab With Subcutaneous Trastuzumab and a Taxane in Patients With HER2-positive Metastatic Breast Cancer (SAPPHIRE). <i>Clinical Breast Cancer</i> , 2019, 19, 216-224.	2.4	13
9	Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE). <i>Annals of Oncology</i> , 2019, 30, 766-773.	1.2	78
10	Improved relapse-free survival on aromatase inhibitors in breast cancer is associated with interaction between oestrogen receptor- $\alpha$ and progesterone receptor- $\beta$ . <i>British Journal of Cancer</i> , 2018, 119, 1316-1325.	6.4	9
11	Hormone receptor positive, HER2 negative metastatic breast cancer: Impact of CDK4/6 inhibitors on the current treatment paradigm. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2018, 14, 3-11.	1.1	4
12	Emerging data and future directions for CDK4/6 inhibitor treatment of patients with hormone receptor positive HER2-negative amplified metastatic breast cancer. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2018, 14, 12-21.	1.1	1
13	Maintaining Dose Intensity of Adjuvant Chemotherapy in Older Patients With Breast Cancer. <i>Clinical Breast Cancer</i> , 2018, 18, e1181-e1187.	2.4	10
14	The open-label, multinational, multicenter, Phase IIIB umbrella study of subcutaneous trastuzumab with or without chemotherapy or pertuzumab in patients (pts) with HER2-positive early breast cancer (EBC) or metastatic breast cancer (MBC): Pooled analysis of safety data from the UmbHER1 program. <i>European Journal of Cancer</i> , 2018, 92, S105-S106.	2.8	1
15	EMBRACA: Efficacy outcomes in clinically relevant subgroups comparing talazoparib (TALA), an oral poly ADP ribose polymerase (PARP) inhibitor, to physician's choice of therapy (PCT) in patients with advanced breast cancer and a germline BRCA mutation.. <i>Journal of Clinical Oncology</i> , 2018, 36, 1069-1069.	1.6	4
16	Management of aromatase inhibitor induced musculoskeletal symptoms in postmenopausal early Breast cancer: A systematic review and meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 111, 66-80.	4.4	49
17	Absent progesterone receptor expression in the lymph node metastases of ER-positive, HER2-negative breast cancer is associated with relapse on tamoxifen. <i>Journal of Clinical Pathology</i> , 2017, 70, 954-960.	2.0	10
18	Abstract P4-21-31: Updated safety results from the first multicenter, open-label, phase IIIb study investigating the combination of pertuzumab with subcutaneous trastuzumab and a taxane in patients with HER2-positive metastatic breast cancer (SAPPHIRE). , 2017, , .		3

#	ARTICLE	IF	CITATIONS
19	Abstract OT2-01-13: A phase 3, open-label, randomized, 2-arm international study of the oral dual PARP inhibitor talazoparib in germlineBRCAmutation subjects with locally advanced and/or metastatic breast cancer (EMBRACA). , 2017, , .		0
20	Management of patients treated with pertuzumab in the Australian clinical practice setting. Asia-Pacific Journal of Clinical Oncology, 2016, 12, 5-15.	1.1	0
21	Hormone receptor positive, HER2 negative metastatic breast cancer: A systematic review of the current treatment landscape. Asia-Pacific Journal of Clinical Oncology, 2016, 12, 3-18.	1.1	8
22	Hormone receptor positive, HER2 negative metastatic breast cancer: Future treatment landscape. Asia-Pacific Journal of Clinical Oncology, 2016, 12, 19-31.	1.1	2
23	Cisplatin versus carboplatin: comparative review of therapeutic management in solid malignancies. Critical Reviews in Oncology/Hematology, 2016, 102, 37-46.	4.4	219
24	Abstract P4-14-12: Interim results from the first open-label, multicenter, phase IIIb study investigating the combination of pertuzumab with subcutaneous trastuzumab and a taxane in patients with HER2-positive metastatic breast cancer (SAPPHIRE). Cancer Research, 2016, 76, P4-14-12-P4-14-12.	0.9	3
25	Management of aromatase inhibitor-associated musculoskeletal symptoms: A systematic review.. Journal of Clinical Oncology, 2016, 34, 157-157.	1.6	0
26	Randomized phase 2 study of carboplatin and bevacizumab in recurrent glioblastoma. Neuro-Oncology, 2015, 17, 1504-1513.	1.2	122
27	Abstract OT3-1-03: An open-label, multicentre, phase IIIb study with intravenous administration of pertuzumab, subcutaneous trastuzumab, and a taxane in patients with HER2-positive metastatic breast cancer (SAPPHIRE). , 2015, , .		1
28	Toxic optic neuropathy in the setting of docetaxel chemotherapy: a case report. BMC Ophthalmology, 2014, 14, 18.	1.4	19
29	Use of myocardial deformation imaging to detect preclinical myocardial dysfunction before conventional measures in patients undergoing breast cancer treatment with trastuzumab. American Heart Journal, 2009, 158, 294-301.	2.7	197
30	Single institution outcomes of treatment of severe aplastic anaemia. Internal Medicine Journal, 2001, 31, 337-342.	0.8	3